In summary, this study suggests that aberrant CDK5 activity promotes sporadic forms of MTC by modulating the expression of cell cycle proteins and points to these as possible biomarkers or targets for the development of new therapies. The gene discussed is PROS1; the disease is medullary thyroid gland carcinoma.